Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Children newly diagnosed with Crohn's disease may benefit from early treatment with the biologic drugs known as anti-TNF-α agents, according to a new study in Gastroenterology1, the official journal of the American Gastroenterological Association.
"While the use of biologic drugs, such as infliximab or adalimumab, is generally reserved for patients who have failed previous therapy for Crohn's disease, little is known about outcomes following the earlier use," said study author Jeffrey S. Hyams, MD, from Connecticut Children's Medical Center, Hartford. "This new research finds that, in children newly diagnosed with moderate to severe Crohn's disease, early anti-TNF-α therapy is more effective at achieving remission than the current standard treatment."
Using data from the RISK Stratification Study, an ongoing, prospective observational research program currently involving 28 pediatric gastroenterology centers in North America, researchers compared the effectiveness of early (within three months after diagnosis) treatment with anti-TNF-α inhibitors, compared with early treatment with immunomodulatory drugs, in attaining clinical remission and facilitating growth in children with Crohn's disease. The current standard of care is corticosteroids followed by the early introduction of immunomodulatory drugs.
At one-year, 85 percent of patients receiving early anti-TNF-α therapy alone were in corticosteroid-free clinical remission, a significantly greater proportion than those treated with either early immunomodulators alone (60 percent) or no early immunotherapy (54 percent). Further, at one-year, no patients in the early anti-TNF-α group had a Pediatric Crohn's Disease Activity Index of greater than 30, compared with 7 percent in the early immunomodulators group and 10 percent in the no early immunotherapy group. Only in the early anti-TNF- α group was normal growth velocity established.
Research funding for this study was provided by the Crohn's and Colitis Foundation of America.
1 Walters TD et al. Increased Effectiveness of Early Therapy With Anti–Tumor Necrosis Factor-α vs an Immunomodulator in Children With Crohn's Disease. Gastroenterology 2014; 146(2): 383-391.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Crohn's / IBD category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
American Gastroenterological Association. "Relief for children newly diagnosed with crohn's disease offered by biologic agents." Medical News Today. MediLexicon, Intl., 5 Feb. 2014. Web.
20 Apr. 2014. <http://www.medicalnewstoday.com/releases/272143>
American Gastroenterological Association. (2014, February 5). "Relief for children newly diagnosed with crohn's disease offered by biologic agents." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/272143.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT is the registered trade mark of MediLexicon International Limited.